GA-UNIBLOC-PUMP
8.9.2021 13:17:10 CEST | Business Wire | Press release
Unibloc Pump , a 37-year leader in the manufacture of positive displacement pumps, strainers, valves, bubble traps, and other solutions for sanitary flow control applications, today announced the acquisition of Flotronic Pumps , a UK-based manufacturer of specialized, air operated double diaphragm (AODD) pumps, and associated accessories. Founded in 1990, Flotronic Pumps has a global reputation as the inventor of the ‘One Nut’ AODD pump. Flotronic Pumps’ pioneering single bolt design significantly reduces process downtime by simplifying pump assembly / disassembly, providing savings in maintenance costs along with best-in-class air pump performance. Flotronic Pumps serves more than 1,000 global companies operating manufacturing facilities of iconic brands in food and beverage, consumer product goods, cosmetics, pharmaceuticals, and other critical process manufacturing applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005041/en/
Terms of the agreement were not disclosed. Flotronic Pumps will be solely owned by US-based Unibloc Pump while retaining its name, Flotronic Pumps Ltd. Joining the leadership team at Flotronic Pumps as chief executive officer will be Chris Stevens, the CEO of Unibloc Pump. Stevens will provide commercial leadership with strengths in business-to-business marketing, channel management, sales, and overall business management.
“This acquisition is a perfect hand-in-glove fit for Unibloc Pump.” Stevens said. “Unibloc Pump and Flotronic Pumps are ready to drive accelerated growth by offering customers products and solutions fueled by our passions for innovation, safety, and simplicity in maintenance to avoid downtime and increase efficiencies,” Stevens added.
Through the leadership of owner Stuart Whitehouse and the deep expertise of Director of Sales Leighton Jones, Flotronic Pumps has witnessed significant growth in Europe, as well as North America. “What we really like most of all about joining the Unibloc Pump family is that we share many of the same cultural values of simplicity in product design, quality in products, unabashed customer-focus, deep industry expertise, and a penchant for strong innovation,” said Jones. “These qualities will ensure that Unibloc Pump and Flotronic Pumps will be successful moving forward by flourishing through common bonds,” added Jones.
“Important to this acquisition is that both companies share complementary market footprints,” commented Whitehouse. “The combination will enable Unibloc Pump to grow its UK and European business, while also giving Flotronic Pumps an unmatched North American foothold. That should pay off in greater market coverage and increased overall value delivered to the customer,” Whitehouse added.
Unibloc Pump seeks to expand its vision to build a global sanitary flow control platform that delivers operational excellence, while targeting highly regulated hygienic end market applications, such as food and beverage, meat and poultry, and pharmaceutical processing. Unibloc Pump’s investment in Flotronic Pumps will provide resources to allow both companies to continue to grow and strengthen their global businesses.
The acquisition will allow Flotronic Pumps to leverage Unibloc Pump’s operational, manufacturing, sales, and distribution capabilities in North America out of its Kennesaw, GA facility. Likewise, Unibloc Pump will utilize Flotronic Pumps’ operations, manufacturing, sales, and distribution footprint in the United Kingdom and other European markets to further complement Unibloc’s existing European operation, Unibloc-R&H GmbH , based in Beckum, Germany.
Unibloc Pump is a portfolio company of May River Capital, a Chicago-based private equity firm devoted to helping high-caliber, lower middle-market industrial businesses grow and thrive. May River Capital takes pride in its unique approach and track record of building businesses through long-term partnership and collaboration. Its leadership team has broad experience helping promising companies become successful mid-size industrial businesses.
ABOUT UNIBLOC PUMP
Since 1984, Unibloc Pump has provided manufacturers in the food and beverage, pharmaceutical, bakery and confection, meat and poultry, brewery, and transportation industries with precision-engineered sanitary pumps, strainers, valves, bubble traps, and other accessory products to tackle the toughest sanitary jobs. Unibloc Pump is the premier designer of efficient, easy-to-clean pumps that help customers fight downtime, achieve a lower cost of operation, and meet deadlines with confidence. For more information, please visit www.uniblocpump.com .
ABOUT FLOTRONIC PUMPS
Based in West Sussex, United Kingdom and founded in 1990, Flotronic Pumps is a manufacturer of specialized AODD pumps and associated accessories. Flotronic’s products take performance far beyond traditional style AODD pump technology with a distinctive single bolt design that allows for in-line assembly / disassembly to be accomplished quickly and efficiently, significantly reducing process downtime, while providing best-in-class performance. For more information, please visit www.flotronicpumps.com .
ABOUT MAY RIVER CAPITAL
May River Capital is a Chicago-based private equity firm focused on investing in lower middle-market, industrial growth companies. May River Capital invests in high-quality industrial growth businesses, including precision manufacturing, engineered products and instrumentation, specialized industrial services, and value-added industrial distribution services. For more information, please visit www.mayrivercapital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom